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W ITH THE INTRODUCTION of inten- sive care units in the 1960s an environ- 
ment was established for aggressive patient care. 
Current technologic achievements continue to 
improve the means by which this care is pro- 
vided. Hemodialysis, ventilators, parenteral nutri- 
tion, and ventricular assist devices all offer tempo- 
rary, or occasionally permanent, support for 
failing organ systems. Extracorporeal circulation 
devices, utilizing pumps and external oxygen- 
ators, represent one of the most powerful tools 
available to the intensivist, surgeon, or neonatol- 
ogist. They can provide pulmonary or combined 
cardiopulmonary support. The technique of extra- 
corporeal circulation has been available and in 
use for the past 20 years. It has become an 
accepted form of therapy in the management of 
neonates with respiratory failure, secondary to 
pulmonary hypertension, infection, or toxic aspi- 
ration. Its role in the management of pediatric 
and adult respiratory or cardiac failure is becom- 
ing more clearly defined. It is incumbent that the 
intensivist understand the potential benefits of 
extracorporeal life support (ECLS), its proper 
applications and inherent complications, to fully 
incorporate this therapeutic modality in patient 
management. 
HISTORIC ASPECTS 
Extracorporeal life support dates back to the 
development of the first heart-lung machine by 
Gibbon in 1936.’ The ability to externally oxygen- 
ate and pump blood prompted the evolution of 
cardiac surgery in the 1950s. Technical consider- 
ations in the design of external oxygenators 
resulted in the “membrane lung” which permit- 
ted prolonged bypass without excessive protein 
denaturation or hemolysis.2-4 Several studies in 
animals demonstrated its safety and efficacy.5-7 
Extracorporeal bypass in a nonoperative setting 
for the purpose of providing oxygenation to 
patients with severe respiratory failure was at- 
tempted in the late 1960s. The first successful 
case occurred in 197 1 when a 24-year-old man, 
who sustained multiple injuries after being struck 
by a car, was managed for 75 hours with extracor- 
poreal oxygenation during the acute phase of 
“shock lung syndrome.“’ Several other success- 
ful cases followed, and a potential role for extra- 
corporeal membrane oxygenation (ECMO) in 
the management of patients with adult respira- 
tory distress syndrome (ARDS) began to 
emerge.‘.” In 1975, a prospective randomized 
study, funded by the National Institutes of Health 
(NIH) was initiated to assess the efficacy of 
ECMO in the management of ARDS.‘* Study 
results did not demonstrate a significant differ- 
ence in survival rates between patients managed 
with ECMO (9.5%) or conventional ventilator 
therapy (8.3%). I3 Enthusiasm for ECMO sub- 
sided, except in a few centers throughout the 
world. In the United States, the application of 
ECMO was redirected from adults to neonates. 
Neonatal respiratory failure, which is usually a 
temporary consequence of prematurity or abnor- 
mal postnatal shunting of blood, provided an 
ideal clinical problem for ECMO management. 
The goal was to support the neonate until persis- 
tent fetal shunting of blood or pulmonary imma- 
turity resolved, while preventing the barotrauma 
associated with mechanic ventilation. Several 
clinical trials using ECMO for neonatal respira- 
tory failure occurred in the late 1960s and early 
1970s but no patient survived.7*‘4s’5 In 1975, 
Bartlett et al reported the first successful neona- 
tal survivor in which ECMO was used.16 Since 
that successful case, two studies have prospec- 
tively documented ECMO’s therapeutic benefit 
in the management of neonatal respiratory 
failure.“,” 
In Europe, several investigators continued to 
explore the role of ECLS in the management of 
adults with ARDS. Gattanoni et al has clearly 
improved on the results obtained in the 1975 
NIH study. His clinical studies have been sup- 
ported by extensive laboratory investigations by 
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Kolobow at the NIH. These studies demonstrate 
the irreversible and permanent pulmonary paren- 
chymal changes that mechanic ventilation may 
cause. 
Emphasis on the specific function and role of 
ECLS in patient management has resulted in 
several acronyms which attempt to summarize 
its therapeutic goals. Extracorporeal membrane 
oxygenation is clearly the most commonly used 
descriptor in the United States. As implied, 
ECMO focuses on the oxygenating aspects of 
ECLS. Extracorporeal membrane oxygenation is 
a carry-over from operative bypass surgery, in 
which the primary goal is to provide oxygenation 
for the blood as it is bypassed around the heart 
and lungs. The device used to perform this task is 
a membrane lung. In Europe, the benefits of 
ECLS are not realized for its ability to provide 
oxygen, but for its ability to remove carbon 
dioxide. With this particular focus, extracorpo- 
real carbon dioxide removal (ECCO,R) became 
the appropriate acronym. Although the circuitry 
and devices used for ECMO and ECCO,R are 
nearly the same, the philosophy of their use and 
other management issues vary. In Japan, extra- 
corporeal lung assist (ECLA) attempts to empha- 
size both the oxygenating and CO,-removing 
functions of the lung. An older term, cardiopul- 
monary support (CPS), is occasionally used to- 
day. To be more generic and broad in our view of 
the role of external lungs (membrane or hollow 
fiber), roller pumps, heat exchangers, etc, we 
have adopted the term extracorporeal life sup- 
port to describe the entire management process. 
These basic circuit components do not constitute 
the entire therapy provided. Hemofilters may be 
added to compensate for injured or failing kid- 
neys. Mechanic ventilation, whether delivered by 
air jets, pressure limits, or tidal volumes, is, 
likewise, inseparable from patient therapy. Other 
support devices and medications including chest 
tubes, parenteral nutrition, cardiotonic drugs, 
antibiotics, and monitoring devices integrate with 
ECMO, ECC02R, or ECLA in patient manage- 
ment of patients. This paper will introduce the 
theoretic indications, practical management is- 
sues, and therapeutic goals of ECLS, as it per- 
tains to both the neonatal, pediatric, and adult 
populations. 
METHODS OF BYPASS 
Two forms of extracorporeal bypass are avail- 
able; veno-arterial (V-A) and veno-venous (V- 
V). In V-A bypass, blood is siphoned from the 
central venous system and reinfused, after pass- 
ing through the bypass circuit, into a major 
artery. This form of bypass has two functions. It 
exchanges gas in the membrane lung, and it 
provides hemodynamic support by delivering flow 
and a pressure head into the arterial system. It is 
ideally suited for the patient who experiences 
respiratory and cardiac failure simultaneously. 
The primary disadvantage of V-A bypass is that 
it can produce distal ischemic symptoms if insuf- 
ficient collaterals are present about the arterial 
vessel used for cannulation. Emboli, either from 
the catheter tip or the circuit, can likewise lead to 
tissue loss and organ dysfunction. 
Veno-venous bypass is suited for the patient 
who has isolated respiratory failure with ade- 
quate cardiac reserves. Blood is siphoned from 
the central venous system, as in V-A bypass, but 
it is reinfused into a major peripheral vein. The 
resulting effect is that the central venous blood 
becomes oxygenated and partially cleared of CO, 
before entering the lungs. Unlike V-A bypass, all 
blood will pass through the right heart and lungs 
and not be shunted around them. Some recircula- 
tion of blood through the bypass circuit occurs, 
but adequate gas exchange can still be accom- 
plished. Veno-venous bypass avoids the sacrifice 
of a major artery and the consequent potential 
morbidity. Emboli released into the reinfusion 
line are trapped either in the membrane lung or 
native lungs, rather than in the arterial circula- 
tion. It provides no hemodynamic support. 
CANNULATION 
Cannulation for bypass occurs in the intensive 
care unit with full support from an operative 
team. The patient should have an indwelling 
arterial line, along with a transcutaneous oxygen 
saturation sensor for continuous monitoring dur- 
ing cannulation and initiation of bypass. After 
administering local anesthetic, an incision is 
made over the target vessels which are dissected 
free from the surrounding tissues. A loading dose 
of heparin (100 U/kg) is given for subsequent 
anticoagulation. The cannulas are placed into 
major vessels through extrathoracic dissections 
of the vascular branches. The largest sized can- 
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nula is inserted to permit maximum blood siphon- 
ing from the venous line, and to avoid overpressur- 
izing the circuit on the arterial side. Venous 
drainage is usually accomplished by a catheter 
placed through the right internal jugular vein 
into the right atrium. Other drainage sites in- 
clude the common femoral, and the external or 
common iliac veins. Reinfusion sites for V-A 
bypass include the right common carotid artery, 
and, less frequently, the axillary or superficial 
femoral arteries, Reinfusion sites for V-V bypass 
include the common femoral, saphenous, or inter- 
nal jugular veins. A neonatal double lumen 
catheter, recently developed and tested at our 
institution, permits both siphoning and reinfu- 
sion of blood to occur into the right atrium with a 
single catheter. ‘9*20 The catheter has a 14 french 
outer diameter. Its inner lumen is disproportion- 
ately divided by septum. The larger channel 
primarily siphons blood through the tip of the 
catheter. Reinfusion occurs in the smaller lumen 
and out side holes in the catheter which preferen- 
tially direct blood into the right ventricle. An 
adult-sized double lumen catheter was described 
by Pesenti et al in 1982.21 
EXTRACORPOREAL LIFE SUPPORT CIRCUIT 
The circuits for all types of bypass support 
(ECMO, ECCO,R, ECLA) consist of the same 
fundamental components. The circuit is built 
from polyvinyl chloride (PVC) tubing, l/4 to 
3/8 inch in diameter, and standard polycarbon- 
ate connectors. From the venous cannula, blood 
is removed at 100 cm of siphon drainage to a 
servoregulator with an expandable silicone rub- 
ber bladder and a microswitch which controls a 
double occlusion roller pump. When pump out- 
flow exceeds venous drainage, the silicone blad- 
der will collapse. This volume change is sensed by 
the microswitch which interrupts power to the 
roller pump. Pump flow stops, while venous 
drainage continues, replenishing the volume in 
the collapsed bladder. Once the bladder’s volume 
is restored, the microswitch will return power to 
the roller pump and permit flow to resume in the 
bypass circuit. Without servoregulation of pump 
flow, excessive suction could be applied in the 
venous line and to the side holes in the venous 
catheter, causing cavitation of dissolved gasses, 
hemolysis, and damage to the vessel endothe- 
hum. From the roller pump, blood travels to a 
membrane or hollow fiber oxygenator which 
provides the gas exchange. The exposed tubing 
and large surface area of the membrane lungs 
cool the blood as it passes through the circuit. A 
heat exchanger is therefore incorporated into the 
circuit after the membrane lung to rewarm the 
blood before it is returned to the patient. Between 
the two patient-connecting lines is a bridge of 
PVC tubing. This bridge permits recirculation of 
blood through the bypass circuit during cannula- 
tion and trials off bypass. Fig 1 schematically 
illustrates the basic circuit components and addi- 
tional monitoring devices frequently incorpo- 
rated. 
The size of the circuit and its components 
depend on the size of the patient and anticipated 
flow requirements. For V-A bypass, each circuit 
is designed to permit flows that will be compara- 
ble to the patient’s cardiac output. Flows of 120 
to 170 cc/kg/min are adequate for a neonate, 80 
to 100 cc/kg/min for a young child, and 70 to 90 
cc/kg/min for an adult. An appropriately-sized 
membrane lung must be selected to accommo- 
date the anticipated flow rate through the circuit. 
Membrane lungs are characterized by their rated 
flow, which is the maximum flow rate at which 
blood, entering the oxygenator 75% saturated, 
will leave 95% saturated. Neonatal circuits typi- 
cally incorporate membrane oxygenators with 
0.4 to 0.8 m2 of surface area, pediatric circuits 
with 1.5 to 2.5 m2, and adult circuits with 3.5 to 
4.5 m2. For V-V bypass, the anticipated flow 
rates will differ, and depend on the type of gas 
exchange desired. If V-V bypass is to provide 
oxygenation in addition to CO, removal, antici- 
pated flow rates should be approximately 20% 
higher than those for V-A bypass.22 If the goal is 
strictly CO, removal, flow rates may be up to 
75% less than the anticipated cardiac output.23 
For adequate CO, removal in the latter case, a 
much larger lung is used relative to the antici- 
pated flow and patient size. In a low-flowing 
circuit, more than one lung is occasionally re- 
quired to effect sufficient CO, clearance to pro- 
duce eucapnia in arterial blood. 
Several small variations in circuit design occur 
between different ECLS centers. The most impor- 
tant differences are the means of servoregulation 
and flow delivery. Instead of bladder reservoirs 
for servoregulation, some circuits employ in-line 
pressure transducers. When circuit pressure falls 
SINARD AND BARTLETT 
A O N C  
Arch 
Fluid 
below a preset value on the venous line or rises 
above a preset value on the arterial side, pump 
flow will progressively slow, thereby normalizing 
any changes. In France, nonocclusive double- 
stage rotor roller-pumps (Rhone-Poulenc, Paris, 
France) are used. Their rotating heads drive flow 
by pinching off segments of a collapsible piece of 
silicone raceway tubing that accepts the venous 
drainage. When venous drainage is insufficient, 
the amount of blood delivered will proportion- 
ately fa11.24 Other centers use centrifugal pumps 
to deliver flow. We have found that these pumps 
cause excessive hemolysis when compared with 
roller pumps. 25 Tidal flow bypass, where blood is 
siphoned and reinfused through the same single 
lumen catheter, has also been attempted.26*27 
PHYSIOLOGY OF EXTRACORPOREAL LIFE 
SUPPORT 
Extracorporeal circulation significantly alters 
the hemodynamic and pulmonary physiology of 
the treated patient. A goal of all forms of ECLS 
is the provision of adequate gas exchange, while 
reducing the barotrauma of conventional positive 
pressure ventilation. When a patient is placed on 
bypass, the amount of pressure support previ- 
ously provided by a ventilator is reduced to “rest 
Fig 1. Basic circuit components 
and monitoring devices incorporated 
in ECLS. 
settings.” These generally include a peak inspira- 
tory pressure of 20 cm H,O, with a positive 
end-expiratory pressure (PEEP) of 5 cm H,O, at 
a rate of 10 to 20 breaths per minute, and an 
inspired oxygen concentration (FiO,) of 21%. 
Other settings are possible, and depend on the 
patient’s pulmonary disease process. High PEEP 
has been used to maintain alveolar expansion in 
neonates and may lead to a shorter course on 
bypass.*s In patients with large air leaks from 
pneumothoracies or bronchopleural fistulas, low 
continuous positive airway pressure is often suc- 
cessful. Low frequency positive pressure ventila- 
tion (LFPPV), commonly used in adults, pre- 
serves functional residual capacity by maintaining 
inflation with 15 to 20 cm H,O PEEP on a 
background ventilator rate of 4 to 6 breaths per 
minute.29 Nearly any form of airway manipula- 
tion is possible, including extubation or frequent 
pulmonary lavages. The common denominator of 
all these options is the avoidance of high peak 
airway pressures. 
With V-A bypass, manipulation of both car- 
diac output and gas exchange occurs simulta- 
neously. Up to 80% of the venous return can be 
siphoned from the right atrium and diverted 
through an ECLS circuit. This blood, after being 
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oxygenated, is then returned into the patient’s 
aortic arch, mixing with the blood pumped from 
the left ventricle. The total cardiac output will be 
the sum of the patient’s own cardiac output and 
the bypass flow rate. The hemoglobin saturation 
will be determined by the rate of bypass flow and 
the function of the native lungs. Blood from an 
ECMO circuit will always be 100% saturated if a 
properly sized and functioning lung has been 
selected. The saturation of blood leaving the 
patient’s native lungs will be considerably less 
and will depend on the amount of pulmonary 
dysfunction and the level of ventilator support 
provided. If at least 80% of the cardiac output 
can be captured by the bypass circuit, the pa- 
tient’s hemoglobin saturation will approach 95% 
to 100%. As a patient’s own lungs recover, the 
amount of gas exchange provided by blood flow 
through a membrane lung can be reduced. In 
V-A bypass, this simply involves reducing the 
rate of bypass flow, which will permit more blood 
to pass from the right atrium into the pulmonary 
artery, rather than into the venous cannula. 
Veno-arterial bypass also provides hemody- 
namic support and improves oxygen delivery to 
peripheral tissues. Our V-A bypass circuit incor- 
porates an in-line blood saturation monitor which 
inserts into the circuit immediately before the 
bladder reservoir (Fig 1). A continuous display of 
the mixed venous saturation (SvO,) is invaluable 
in selecting proper bypass flow rates. A low SvO, 
indicates either inadequate oxygen delivery or 
excessive oxygen consumption. Important compo- 
nents of oxygen delivery include cardiac output, 
hemoglobin concentration, and hemoglobin satu- 
ration. Management of patients on V-A bypass 
requires optimizing each of these variables. The 
hematocrit is maintained between 45% to 50%. 
Maximal saturation of hemoglobin is ensured by 
delivering more blood to an appropriately-sized 
membrane lung. Increasing circuit flow rates will 
enhance cardiac output in addition to improving 
oxygenation by shunting more blood away from 
the failing lungs. Tissue oxygen consumption can 
be minimized through the use of paralytics, 
sedatives, antibiotics, and modest hypothermia, 
when necessary. Each of these manipulations will 
result in an improvement in SvO, toward the 
desired level near 75%. 
While V-A bypass controls both components 
of oxygen delivery. namely cardiac output and 
hemoglobin saturation, V-V bypass focuses only 
on gas exchange. Veno-venous bypass causes no 
direct improvement in cardiac output; all blood 
delivered to the tissues occurs from the pumping 
action of the left ventricle. Veno-venous bypass 
only alters the gas content of the central venous 
blood. 
Gas exchange in blood consists of both oxygen 
delivery and CO, removal. The amount of gas 
exchange in patients on V-V bypass depends on 
the rate at which blood is siphoned to the 
membrane lung, the size of the lung, and the flow 
rate and composition of the gas ventilating the 
membrane lung. The two components of gas 
exchange are not inseparable. Oxygenation across 
a membrane lung is a function of the amount of 
unsaturated hemoglobin passing through it. In 
V-V bypass, desaturated blood returning to the 
central venous circulation is withdrawn into the 
circuit, oxygenated completely, and then rein- 
fused to mix with more desaturated blood from 
the periphery. If no recirculation of blood existed 
(ie, only desaturated blood from the tissues was 
selectively siphoned into the circuit, and the 
oxygenated blood selectively returned to the 
right ventricle), blood entering the pulmonary 
artery would be 100% saturated. Escape of deox- 
ygenated blood into the right ventricle and recir- 
culation of oxygenated blood back into the circuit 
both contribute to inefficient oxygenation and 
cause the saturation of blood entering the pulmo- 
nary artery to be closer to 80% to 90%. To 
compensate for recirculation, the amount of 
blood actually needed to pass through a mem- 
brane lung to produce better oxygenation will 
frequently be in excess of normal venous return. 
The higher blood flow rates will require the use of 
a lung with a rated flow slightly greater than the 
patient’s expected cardiac output. 
Carbon dioxide clearance across a membrane 
lung depends on the surface area of the lung and 
on the CO, concentration gradient between the 
venous blood and the ventilating gas. If room air 
or oxygen ventilates a membrane lung, the gradi- 
ent will be near 47 mm Hg when the gas flow 
rates are high. At lower sweep rates, CO, will not 
be cleared rapidly from the lung, and the gradi- 
ent may decrease. The surface area of the mem- 
brane lung will determine the area over which 
the CO, gradient can dissipate. A larger surface 
area will permit greater CO2 clearance. If the 
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goal of ECLS is CO, removal rather than oxygen 
delivery, high blood flow rates will not be re- 
quired. Only a portion (usually 30%) of the 
cardiac output needs to be captured by the 
membrane lung to effectively clear all metaboli- 
cally produced CO,. 3o Hemoglobin does not serve 
as a sink for CO, as it does for oxygen; the pC0, 
of blood leaving the circuit will average with that 
of the blood returning from the periphery, after 
equilibrating with bicarbonate and water. A 
large lung with a relatively small amount of 
blood flowing through it can effectively eliminate 
enough CO, to produce eucapnia in mixed venous 
blood. Low-flow V-V bypass will not adequately 
oxygenate blood, since it is the amount of unsat- 
urated hemoglobin, rather than the size of the 
membrane lung, that determines the extent of 
oxygenation possible. 
Occasionally during V-A bypass or in high- 
flow V-V bypass where the goal is oxygenation, 
too much CO, will be removed across the mem- 
brane lung, and a marked respiratory alkalosis 
will ensue. This problem can initially be ap- 
proached by decreasing the rate of gas flow 
ventilating the membrane lung to reduce the 
gradient for CO, diffusion. At very low-sweep 
flows, the efficiency of the membrane lung will 
fall, and oxygen transfer fails. In such circum- 
stances, the lung can be ventilated with carbogen 
(95% 0, and 5% CO,) or a nonstandard mixture 
of 0, and CO,. The amount of carbogen added 
can be titrated to achieve a desired arterial pC0, 
of 40 mm Hg. 
MANAGEMENT OF PATIENTS ON BYPASS 
Caring for patients on ECLS typically re- 
quires a nurse and an ECMO specialist. Extracor- 
poreal membrane oxygenation specialists are 
nurses, respiratory therapists, perfusionists, or 
physicians who have completed an extensive 
course in ECMO physiology and have received 
over 80 hours of bedside instruction and intern- 
ship. They work with the nurse in providing total 
patient care. The ECMO specialist performs all 
circuit manipulations, administers blood prod- 
ucts, adjusts the level of anticoagulation, and 
regulates pump blood flow in prespecified bound- 
aries provided by a physician. The nurse tends to 
patient care needs, medication acquisition and 
dressing changes. 
While on bypass, a patient remains anticoagu- 
lated by a continuous heparin infusion, ranging 
between 15 to 30 U/kg/h. The level of anticoag- 
ulation is monitored by the activated whole blood 
clotting time (ACT). Heparin is titrated to 
maintain an ACT between 180 to 200 seconds. 
Careful attention to urine output, plasma transfu- 
sions, and ACT levels permits a tight control. 
The infinite levels of anticoagulation used during 
operative bypass for cardiac surgery are exces- 
sive and lead to numerous bleeding complications 
during the relatively prolonged course on bedside 
bypass. Significant or unusual clotting within the 
components of the circuit have not occurred at 
this low level of anticoagulation. 
Thrombocytopenia predictably occurs after 
the initiation of bypass, presumably by dilution 
in the circuit and platelet consumption in the 
membrane lung. Platelet transfusions are rou- 
tinely administered at the initiation of bypass 
and periodically to maintain a level greater than 
100,000/mm3. Platelets are transfused into the 
circuit at an infusion port downstream from the 
membrane lung. Thrombocytopenia may occur 
even after bypass has been discontinued, and, in 
light of this risk, platelet count should be moni- 
tored for an additional 4 days.31 Oozing from 
operative sites and blood sampling require peri- 
odic blood transfusions to keep the hematocrit 
over 45%. A low level of hemolysis can be 
expected from surface interactions between blood 
cells and the artificial conduits, components, and 
occasional clots in the circuit. The rate of hemol- 
ysis is monitored with free serum hemoglobin 
levels. A level exceeding 30 mg/dL (normal < 5 
mg/dL) may be the first indicator of significant 
clot formation or circuit damage. 
An accurate record of fluid balance is essential 
for patient management. Frequently patients are 
edematous from prior fluid resuscitation and 
volume administration at the initiation of bypass. 
After 24 to 48 hours of stabilization, a diuresis 
towards dry weight is initiated with mannitol or 
furosemide. Hemofiltration can supplement urine 
output in patients that do not satisfactorily re- 
spond to diuretics.32 
Patients on ECLS receive the same aggressive 
and supportive care other intensive care unit 
patients require. Nutrition is provided parenter- 
ally or by nasogastric or oral feedings. Prophylac- 
tic antibiotics are given to patients on bypass in 
the absence of specific infections. Stress ulcer 
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and decubeti prophylaxis are likewise provided. 
While a patient is on bypass and anticoagulated, 
care is taken with any invasive procedure. All 
blood sampling occurs through previously estab- 
lished access lines. Other procedures, such as 
chest tube insertions, are performed with electro- 
cautery. 
Management of flow rates has previously been 
described. Optimizing SvO, and blood pressure 
are of major importance in V-A bypass, while gas 
exchange is the goal in V-V bypass. As pulmo- 
nary or cardiac function improves, flow rates can 
be progressively decreased. When flow rates 
reach 20 to 30 cc/kg/mm, a trial off bypass can 
be attempted. In V-A bypass, the patient connect- 
ing lines are clamped and the bridge opened to 
permit recirculation of blood within the circuit. 
In V-V bypass, the ventilating gas to the mem- 
brane lung is removed and the gas ports to the 
membrane lung capped. Blood is still siphoned 
from and returned to the patient, but no gas 
exchange occurs. During weaning attempts, the 
settings of the ventilator are increased to levels 
commensurate with physiologic support. A suc- 
cessful trial off for 45 to 60 minutes, as evidenced 
by adequate oxygenation, CO, removal, and 
hemodynamic stability, can be followed by decan- 
nulation. 
NEONATAL EXPERIENCE 
Neonatal pulmonary failure is distinctly dif- 
ferent from its adult counterpart and usually 
results from pulmonary artery vasospasm. The 
high pulmonary vascular resistance causes blood 
to be shunted from the right to the left heart 
through a patent foramen ovale or ductus arteri- 
osus. This prenatal blood flow pattern is known as 
persistent fetal circulation. The elevated pulmo- 
nary vascular resistance may result from toxic 
aspiration (meconium, blood, amnionic fluid), 
infection (bacterial, viral), immaturity (lack of 
surfactant), unknown causes (primary persistent 
pulmonary hypertension), or structural lesions 
(congenital diaphragmatic hernias). Medical 
measures to release the pulmonary vasospasm, 
including hyperventilation to induce alkalosis or 
tolazoline administration for vasodilation, are 
unsuccessful in 5% to 10% of patients. In these, 
one fourth develop persistent postductal hypox- 
emia, and ultimately die. Several predictors of 
mortality have been developed to quantitate 
degrees of respiratory failure while a patient is 
supported by a ventilator. At the University of 
Michigan Medical Center (UMMC; Ann Arbor, 
MI), the oxygenation index (01) has been used. 
The 01 is calculated as the product of the mean 
airway pressure x FiO, x lOO/postductal par- 
tial arterial oxygen pressure (Pa0,).33 Values 
greater than 40 are associated with an 80% to 
90% mortality, while those greater than 25 are 
associated with a 50% mortality. Some centers 
use an alveolar to arterial oxygen gradient as an 
indicator of clinical dysfunction, with values 
greater than 600 to 620 indicative, of a 90% 
mortality.34’35 Others have found that a ratio of 
arterial to alveolar oxygen partial pressures 
(Pa02/PA02) less than 0.15 to be associated 
with an 80% predicted mortality.‘a A universally- 
accepted measure or index of respiratory failure 
has yet to be developed. The original pulmonary 
insufficiency index (PII), calculated on the basis 
of an effective alveolar to arterial gradient over 
time, is more cumbersome than the above meth- 
ods and is no longer used.36,37 
The goal of ECMO in the management of 
neonates is to provide oxygenation until the 
persistent fetal circulation reverses (usually 4 to 
5 days), and avoid the barotrauma associated 
with mechanic ventilation. The complications of 
barotrauma caused by ventilators includes pneu- 
momediastinum, pneumothoracies, diminished 
cardiac output, and the late development of 
bronchopulmonary dysplasia. In neonates, V-A 
bypass is more commonly used than V-V bypass. 
It has, up to now, been technically simpler than 
V-V. Only one surgical incision is required, and 
cannulation is more easily accomplished in the 
common carotid artery than in the femoral or 
external iliac veins. Persistent leg swelling occurs 
with ligation of these veins and poses a trouble- 
some late complication. A new neonatal double 
lumen catheter obviates the technical concerns of 
V-V bypass previously performed with two sepa- 
rate cannulas. Only one incision is required, and 
one vessel is cannulated. Excellent oxygenation 
can be provided and, in recent experiences, very 
few patients require conversion to V-A bypass for 
hemodynamic support. ” Neither V-A nor V-V 
bypass has been shown to be superior in its ability 
to reverse persistent fetal circulation.‘* 
The indication for ECMO in neonates is rela- 
tively straight forward; failure of conventional 
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management. As noted, each center may vary in 
its measure of progressive respiratory failure. At 
UMMC, three out of five postductal arterial 
blood gasses, drawn 30 minutes apart, demon- 
strating an 01 greater than 40 represents a clear 
indication, while 01s greater than 25 represent a 
relative indication. Other relative indications 
include severe barotrauma or rapid and acute 
deterioration in respiratory function. 
Contraindications to ECMO seek to identify 
patients who are not likely to benefit from ECMO 
or who are likely to succumb to a complication of 
anticoagulation. 4o Prematurity a nd low birth 
weight are both associated with an increased 
incidence of intracranial hemorrhage.4’ Neo- 
nates with gestational age less than 35 weeks who 
have been placed on ECMO suffered a high 
incidence of intracranial hemorrhage and a 75% 
immediate mortality after ECMO was discon- 
tinued.42 Previous intracranial hemorrhage, as 
demonstrated by a preoperative ultrasound, is 
likely to worsen with anticoagulation, and repre- 
sents an additional contraindication. Postductal 
hypoxemia, due to congenital cardiac malforma- 
tions, must also be ruled out with an echocardio- 
gram before ECMO is initiated. Mechanical 
ventilation greater than 10 days is associated 
with a high incidence of bronchopulmonary dys- 
plasia and irreversible parenchymal changes, 
prohibitively reducing the benefits of ECMO. 
Neonates with severe congenital anomalies or 
neurologic deficits incompatible with a meaning- 
ful existence are typically not considered as 
candidates for heroic and aggressive manage- 
ment. 
Complications that occur in neonates on by- 
pass fall into three broad categories: bleeding, 
circuit-related, and physiologic. Bleeding is com- 
mon, and occurs in 20% to 40% of patients. Its 
severity ranges from minor oozing at the cannula- 
tion site to grade IV intracranial hemorrhage. 
Intracranial hemorrhage is most serious but 
occurs in only 14% of full term neonates (> 35 wk 
gestational age). 42 There were, on average, 0.28 
mechanic complications per case during the first 
7 15 neonates placed on bypass.43 These included 
oxygenator failure (7%), tubing rupture (3%), 
pump failure (2%), heat exchanger malfunction 
(I%), cannula-related problems (7%), and miscel- 
laneous problems (7%). They created only tempo- 
rary physiologic instability, and none were associ- 
ated with a decreased patient survival rate 
compared with overall survival rate. Physiologic 
complications occurred 1.77 times per case, and 
included hematologic changes, seizures, electro- 
lyte imbalances, arrhythmias, renal dysfunction, 
sepsis, etc. The incidence of physiologic complica- 
tions decreased as the experience of an ECMO 
center increased. Circuit-related problems are 
likewise decreasing, as better parts and compo- 
nents are developed. 
The efficacy of ECMO has been measured in 
terms of survival. Initial studies demonstrated an 
improved survival compared with historic 
controls.44 The first prospective randomized con- 
trolled study, using a “randomized play-the- 
winner” statistical method, showed that ECMO 
improved survival when compared with conven- 
tional management.45g17 Using identical entry 
criteria, the single patient assigned to conven- 
tional management for respiratory insufficiency 
died while all nine of the patients assigned to 
ECMO management survived. These findings 
were supported by a second prospective, random- 
ized study which likewise demonstrated a signifi- 
cantly improved survival rate with ECM0.18 
Four of 10 patients assigned to conventional 
therapy died, while 28 of 29 assigned to ECMO 
survived. The study was terminated once a P 
value of .05 was reached. 
Table 1 summarizes a recent compilation of 
data from neonates treated with ECM0.46 The 
most frequent diagnosis is meconium aspiration 
syndrome, occurring 36.4% of the time. The best 
results occur in patients with meconium aspira- 
tion syndrome (survival rate, 92.5%). The aver- 
age survival rate of all diagnoses is 82.9%. 
Current survival rates may actually be higher, 
since the values listed are from all patients, 
Table 1. Extracorporeal Life Support for Neonatal 
Respiratory Failure 
Survival Mortality Total No. 
Diagnosis (%I (%I Patients 
Meconium aspiration syndrome 92.5 7.5 1,313 
Respiratory distress syndrome 83.2 16.8 517 
Congenital diaphragmatic hernia 62.5 37.5 546 
Pneumonia/sepsis 76.8 23.2 366 
Persistent fetal circulation 86.8 13.2 456 
Other 74.5 25.5 137 
82.9 17.1 3.335 
Data from the Neonatal ECMO Registry of the Extracorporeal 
Life Support Organization as of January 1 990.46 
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including the earliest cases. A learning curve is 
present at new ECMO centers, and the survival 
rate of the first 20 patients is less than that in the 
remainder.43 The improved survival rate may be 
related to a decrease in physiologic complications 
from 2.26 per case for the first 10 cases to 1.6 per 
case for the remaining patients.43 
Extracorporeal membrane oxygenation has 
been shown to improve survival rates in patients 
with congenital diaphragmatic hernias. In our 
institution, there has been a clear trend (P = .06) 
toward enhanced survival (76%) in patients with 
congenital diaphragmatic hernias after 198 1, 
since ECMO has been available, compared with 
survival rates (50%) prior to the availability of 
ECM0.47 This enhanced survival rate with 
ECMO is not universally present. A multicen- 
tered study involving 93 congenital diaphrag- 
matic hernia patients demonstrated only a 58% 
survival rate in patients managed with ECMO, 
compared with the UMMC study where survival 
in similar patients was 87% (13 of 1 5).48 Mortal- 
ity was associated with intracranial bleeding, 
operative site bleeding, and renal failure. Extra- 
corporeal membrane oxygenation has also been 
used in the neonatal population as a bridge to or 
support after cardiac surgery, including heart 
transplantation.4gY50 
Follow up of neonatal patients treated with 
ECMO has revealed excellent results. In one 
study, 63% of the patients (45 of 72) were normal 
or near normal. Major developmental delay oc- 
curred in 17% (12 of 72) and major pulmonary 
problems occurred in 8% (6 of 72) of neonates51 
Similar success rates have been reported by other 
centers.52’53 There are no control groups with 
whom to compare this complication rate, since 
the predicted mortality of the neonates placed on 
ECMO is 85%. Most neurologic sequelae result 
from perinatal hypoxemia and hypotension which 
occur in up to 50% of similar patients not 
managed with ECM0.54 Carotid artery ligation 
may contribute to some of the neurologic changes 
in the ECMO-treated population, since a prepon- 
derance of unilateral right-sided brain lesions 
have been identified.” 
PEDIATRIC AND ADULT EXPERIENCE 
Enthusiasm for the role of ECLS in ARDS 
rapidly waned when the NIH-sponsored trial of 
1979 did not demonstrate any improved survival 
with ECMO compared with conventional 
management. i3 A retrospective assessment of 
this study reveals several points which cloud or 
obviate the potential benefits of ECMO. In the 
NIH ECMO study, the amount of bleeding from 
the anticoagulation averaged between 1.5 to 2.0 
liters per person per day. Ventilator support was 
often continued at near maximal levels, including 
high pressures with rapid rates, causing contin- 
ued barotrauma. Many patients had been intu- 
bated for several days (average 9.6 days) prior to 
the initiation of ECMO, and probably had preex- 
isting, irreversible pulmonary changes, caused 
either by the disease process or aggressive me- 
chanic ventilation. Seven of the eight surviving 
patients had been intubated for less than 7 days. 
Additionally bacterial and viral pneumonia pre- 
dominated as the main cause of respiratory 
insufficiency. Extracorporeal membrane oxygen- 
ation has been demonstrated to be more effective 
in patients with ARDS than with infections.56 
Continued investigation into the pathophysiol- 
ogy of respiratory failure and the benefits of 
ECLS persisted, predominantly in Europe and at 
the NIH. The role of ECLS took on a new focus, 
that of the prevention of barotrauma induced by 
mechanic ventilation, Kolobow at the NIH, us- 
ing sheep models for lung disease, demonstrated 
the consequences of high pressure ventilation and 
pure oxygen on normal lungs.57 Ventilating 
healthy sheep with a peak inspiratory pressure of 
30 cm H,O, keeping PaCO, normal, caused a 
significant reduction in pulmonary function within 
48 hours; with peak pressures of 50 cm H,O, 
pulmonary deterioration occurred more rapidly 
over 12 to 36 hours. ‘*v5’ Similar findings, along 
with a measured loss of surfactant activity, have 
also been demonstrated to occur in dogs venti- 
lated for 1 to 2 hours with a PIP of 26 to 32 cm 
H,O!’ 
In Milan, Italy, clinical trials continued in 
adults. To reduce the amount of pressure support 
required from a ventilator, Gattinoni et al used 
ECLS to separate the two components of gas 
exchange; O2 delivery and CO2 removal. A pri- 
mary function of respiration, ie, the movement of 
gas into and out of lungs, was viewed to be CO, 
elimination. When CO, was cleared by other 
means (as through extracorporeal removal), alve- 
olar ventilation in otherwise healthy animals was 
shown to significantly decrease or stop.6’ As 
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previously described, ECCO,R is accomplished 
at relatively low-flow bypass rates (20% to 30% 
cardiac output) through an oversized membrane 
lung. The bypass technique is usually V-V. Ade- 
quate oxygenation may occur by a continuous 
flow of oxygen into the alveoli, where it can then 
diffuse down its concentration gradient into the 
capillary blood. The continuous flowing of blood 
preserves this concentration gradient. Apneic oxy- 
gentation has been reported in the past, but its 
usefulness has been limited by CO, accumulation 
and the resultant respiratory acidosis.62,63*64965*G The 
advent of external “oxygenators” or “CO, 
removers” obviates this limiting complication. 
Apneic oxygenation, after several hours, pro- 
duces a loss of functional residual capacity and 
decreases total lung compliance.67 This complica- 
tion is avoided if a few (3 to 4) mechanic breaths 
are delivered every minute to simulate a sigh of 
normal ventilation. The process of delivering a 
continuous flow of oxygen to alveoli by maintain- 
ing PEEP or continuous positive airway pressure 
at 5 to 10 cm H,O with a respiratory rate of 3 to 4 
breaths per minute is referred to as LFPPV. Low 
frequency positive pressure ventilation works 
best when accompanied by V-V bypass, since no 
blood will be diverted from the pulmonary circu- 
lation. Combining LFPPV with ECCO,R theoret- 
ically produces an ideal environment to permit 
pulmonary recovery, providing adequate gas ex- 
change, and preventing additional barotrauma 
from mechanic ventilation. ECCO,R will remove 
metabolically produced CO, to maintain eucap- 
nia (in addition to providing a small amount of 
oxygenation), while LFPPV will provide ade- 
quate oxygen delivery (with a small amount of 
CO, clearance). The safety and efficacy of this 
theory was supported by experimental trials in 
sheep and other animals.68969 
Low frequency positive pressure ventilation 
with ECCO,R is one of several methods by which 
adults and children can be supported by ECLS. 
Veno-arterial or high-flow V-V bypass are also 
possible. Extracorporeal CO, removal requires 
lower blood flow rates; smaller sized catheters 
used for this bypass technique are easier to place 
and usually do not interrupt major peripheral 
vessels. The specific needs and technical issues 
related to individual patient needs will often 
dictate the form of bypass to be initiated. 
The indications for ECLS in the pediatric and 
adult populations are similar to those in the 
neonate with a few modifications. At the UMMC, 
several criteria have been introduced, the most 
important of which is the presence of a reversible 
pulmonary disease process. A transpulmonary 
shunt greater than 30%, despite optimal therapy, 
should exist along with a static pulmonary com- 
pliance of less than 0.5 cc/kg/cm HzO. Signifi- 
cant underlying pulmonary insufficiency or high 
pulmonary artery pressures imply poor pulmo- 
nary reserves, and detract from the benefits 
ECLS may provide. Patients should be intubated 
for less than 7 days. Periods of intubation greater 
than 10 days increase the incidence of 
barotrauma-induced pulmonary fibrosis. Pa- 
tients should be younger than 65 years and have 
no underlying bleeding disorders or contraindica- 
tions to anticoagulation. Additional contraindica- 
tions include major brain injury, or conditions 
incompatible with a favorable long term progno- 
sis. Relative contraindications include immuno- 
suppression (because of a high rate of bacterial 
infection) and multisystem organ failure (be- 
cause of uniformly poor results). 
Tables 2 and 3 summarize the results of the 
pediatric cases entered into the international 
registry. Two broad categories have developed 
for pediatric ECLS support; cardiac and pulmo- 
nary. While intraaortic balloon pumps, intravas- 
cular pumps, implantable ventricular assist de- 
vices, and total artificial hearts can provide 
nonpharmacologic cardiac support in the adult 
population, no such devices exist for the pediatric 
population. Veno-arterial bypass presently is the 
only means by which mechanic cardiac support 
can be delivered to children. Veno-arterial by- 
pass may serve as a bridge to transplantation, 
surgery, or recovery after cardiac surgery. The 
Table 2. Extracorporeal Life Support for Pediatric 
Cardiac Failure 
Diagnosis Survival (%) 
Total No. 
Mortality (%) Patients 
Cardiac surgery 43.1 56.7 123 
Cardiac transplant 33.3 66.7 9 
Myocardopathy 25.0 75.0 4 
Other 50.0 50.0 2 
42.0 58.0 138 
Data from the Pediatric Cardiac ECLS Registry of the Extracor- 
poreal Life Support Organization as of January 1 990.46 
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Table 3. Extracorporeal Life Support for Pediatric 
Pulmonary Failure 
Survival Mortality Total No. 
Diagnosis (%) (%) Patients 
Respiratory distress syndrome 41.4 58.6 29 
Viral pneumonia 45.8 54.2 24 
Aspiration 60.0 40.0 10 
Bacterial pneumonia 0 100 3 
Other 46.7 53.3 15 
44.4 55.6 81 
Data from the Pediatric Pulmonary ECLS Registry of the 
Extracorporeal Life Support Organization as of January 1 990.46 
most common indication for V-A bypass is for 
perioperative cardiac support, occurring in 89.1% 
of the cases. The average survival rate is 42% for 
all diagnoses. The two most common reasons for 
initiating bypass are cardiogenic shock (18.8%) 
and cardiac arrest (15.9%), each with associated 
mortalities of 61.5% and 77.3%, respectively. 
Pulmonary diagnoses account for 37% of the 
diagnoses for initiating ECLS in the pediatric 
population. The two most frequent diagnoses are 
aspiration and viral pneumonia. The overall sur- 
vival rate is 44.4% for all diagnoses. Failure to 
respond to conventional management, the major 
reason for initiating bypass, occurs in 46.2% of 
the cases and has an attendant mortality of 
59.5%. Barotrauma, as an indication, occurs 
second most frequently (28.7%), with an even- 
tual mortality of 56.5%.46 
Relatively few case summaries for adults 
treated with ECLS have been published in the 
last decade. Most of the recent adult experience 
has developed in Europe, predominantly in Italy 
and Germany. Pesenti et al have reported a 
survival rate of 47% in 55 patients treated with 
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Table 4. European Experience With Extracorporeal Life 
Support for Adult end Pediatric Respiratory Failure 
No. of No. of Survival Rate 
Site Patients Survivors (%I 
Marburg, Germany 86 46 53 
Berlin. Germany 8 6 75 
Dusseldorf, Germany 4 1 25 
Milan/Monza, Italy 73 35 48 
Stockholm, Sweden 13 5 38 
Lund 2 2 100 
Paris, France 14 6 43 
200 101 51 
Data presented at the 36th Annual Meeting of ASAIO and 
represent a cumulative summary as of April 1 990.‘3 
LFPPV-ECC02R.” The entry criteria to their 
study were essentially the same as that for the 
NIH ECMO study (PaO, < 50 mm Hg at FiO, 
of 0.60, PEEP of 5 cm H,O or higher) with the 
addition of a total static lung compliance less 
than 30 mL/ccH,O. The NIH ECMO criteria 
resulted in 90% mortality, so the Pesenti et al 
data represents a major improvement compared 
with these historic controls. However, many 
aspects of treatment have changed in the last 
decade, and this historic comparison has been 
questioned.‘] Knoch, in a review of 33 patients 
treated with LFPPV-ECCO,R in Marburg, Ger- 
many, reported that 73% were weaned from 
mechanic ventilation and 55% survived.72 Al- 
though no randomization was present, their re- 
sults were compared with a 100% mortality in 11 
of their patients, who also met ECCO,R criteria 
for treatment but had contraindications. As of 
April 1990, a total of 200 adults and children 
have been treated with ECLS in Europe at seven 
separate centers. The overall survival rate is 5 1%. 
Table 5. Centers in the United States With Major Extracorporeal Life Support Experience for 
Cardiorespiratory Failure in Children 
Center Location Director 
Ochsner Foundation Hospital New Orleans, LA Kenneth Falterman, MD 
Boston Children’s Hospital Boston. MA James Fackler, MD 
Children’s Hospital of Michigan Detroit, Ml Michael Klein, MD 
University of Michigan Medical Center Ann Arbor, MI Robert Bartlett, MD 
Minnesota Regional ECMO Program Minneapolis, MN Thomas Green, MD 
Cardinal Glennon Children’s Hospital St Louis, MO Tom Weber, MD 
St LOUIS Children’s Hospital St Louis, MO Thomas Spray, MD 
Babies Hospital New York, NY Charles Stolar, MD 
Children’s Hospital of Pittsburgh Pittsburgh, PA Ralph Siewers, MD 
John Scaly Hospital Galveston, TX Jay Zwischenberger, MD 
NOTE. This summary was composed in May 1990, and may not be inclusive of all centers. The centers listed have had experience with a 
significant number of pediatric cases. 
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Table 6. Adult Extracorporeal Life Support Centers in North America 
Centsf 
Sharp Hospital 
Pacific Medical Center 
University of Michigan Medical Center 
University of Minnesota Medical Center 
St Louis University Medical Center 
Hershey Medical Center 
LDS Hospital 
Location 
San Diego, CA 
San Francisco, CA 
Ann Arbor, MI 
Minneapolis, MN 
St Louis, MO 
Hershey, PA 
Salt Lake City, UT 
Director 
Walter Dembitsky, MD 
J. Donnald Hill, MD 
Robert Bartlett, MD 
Jerome Abrams, MD 
Glenn Pennington, MD 
Michael Snyder, MD 
Alan Morris, MD 
NOTE. This summary was complied as of May 1990, and may not be inclusive of all centers performing adult ECLS. Centers listed have 
had major experience with adult ECLS. 
Table 4 summarizes the results from these 
centers.73 While convincing data in the adult 
population is not as apparent as in the neonatal 
population, a clear trend towards improved sur- 
vival rates exists. These encouraging results have 
prompted the resumption of adult ECLS in our 
institution. Evolving experience continues to rede- 
fine our indications for bypass. Morris et al are 
carrying out a prospective randomized study to 
reassess the role for ECLS in the management of 
adult respiratory failure.” Tables 5 and 6 are 
lists of centers in the United States that are using 
ECLS for pediatric and adult respiratory failure. 
The future of ECLS lies in the development of 
techniques and devices to make the bypass pro- 
cess less invasive, safer, and simpler in manage- 
ment. Several steps have already been taken 
toward this goal. Heparin-coated circuits, which 
have been in use in Europe, will soon be available 
in the United States. Bleeding complications, 
which affect the great majority of patients treated 
with ECLS, will markedly be reduced or elimi- 
nated. These circuits will also permit the treat- 
ment of a new population of patients: the prema- 
ture neonates who are most susceptable to fatal 
intracranial hemorrhages. The low flows needed 
with ECCO,R permit the use of smaller cathe- 
ters that can be inserted percutaneously without 
the need for surgical incisions. Double lumen 
catheters are entering the United States’ market 
with promising initial results. The neonatal dou- 
ble lumen catheter has simplified the cannulation 
process for this age group with isolated respira- 
tory failure. Smaller-sized catheters, designed 
for low birth weight or premature, infants are 
presently in the developmental process. Adult 
and pediatric double lumen catheters shall shortly 
be available for use in the United States. Comput- 
erized software that integrates patient and cir- 
cuit monitors with the pumping device and venti- 
lator is being developed to simplify patient 
management. New concepts of providing gas 
exchange have emerged. An intravenous gas 
exchange device, recently introduced, eliminates 
the need for external blood conduits and pump- 
ing mechanisms. The “IVOX” resides in the 
caval system in vivo to accomplish 0, delivery 
and CO, removal. 74 The efficacy of this device 
remains to be demonstrated in humans. 
As with all the other new or modified support 
devices, it is important for the physician who 
cares for intensive care patients to be familiar 
with the potential benefits of ECLS. Presently, 
over 50 centers in the United States are able to 
provide ECLS for neonates. Several centers can 
treat children and adults. Transport to one of 
these centers is difficult but widely practiced with 
neonates. Some centers are developing conve- 
nient means to transport children and adults for 
considerable distances while on bypass. The avail- 
ability of ECLS technology is therefore readily 
apparent. Familiarity with the concept of ECLS 
breeds a better understanding as to its applica- 
tions and, ultimately, to improved patient care. 
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